Next Article in Journal
Phage–Bacteria Interactions in Potential Applications of Bacteriophage vB_EfaS-271 against Enterococcus faecalis
Next Article in Special Issue
Immunotherapy and Gene Therapy for Oncoviruses Infections: A Review
Previous Article in Journal
Recovery of Recombinant Avian Paramyxovirus Type-3 Strain Wisconsin by Reverse Genetics and Its Evaluation as a Vaccine Vector for Chickens
Previous Article in Special Issue
Loop-Mediated Isothermal Amplification (LAMP) Assay for Rapid and Accurate Confirmatory Diagnosis of HTLV-1/2 Infection

Viral Vectors for COVID-19 Vaccine Development

PanTherapeutics, CH1095 Lutry, Switzerland
Academic Editor: David A. Schwartz
Viruses 2021, 13(2), 317;
Received: 27 January 2021 / Revised: 11 February 2021 / Accepted: 15 February 2021 / Published: 19 February 2021
(This article belongs to the Special Issue New Techniques in Viral Diagnosis and Therapy)
Vaccine development against SARS-CoV-2 has been fierce due to the devastating COVID-19 pandemic and has included all potential approaches for providing the global community with safe and efficient vaccine candidates in the shortest possible timeframe. Viral vectors have played a central role especially using adenovirus-based vectors. Additionally, other viral vectors based on vaccinia viruses, measles viruses, rhabdoviruses, influenza viruses and lentiviruses have been subjected to vaccine development. Self-amplifying RNA virus vectors have been utilized for lipid nanoparticle-based delivery of RNA as COVID-19 vaccines. Several adenovirus-based vaccine candidates have elicited strong immune responses in immunized animals and protection against challenges in mice and primates has been achieved. Moreover, adenovirus-based vaccine candidates have been subjected to phase I to III clinical trials. Recently, the simian adenovirus-based ChAdOx1 vector expressing the SARS-CoV-2 S spike protein was approved for use in humans in the UK. View Full-Text
Keywords: SARS-CoV-2; COVID-19; vaccines; adenovirus; preclinical immunization; clinical trials; approved vaccine SARS-CoV-2; COVID-19; vaccines; adenovirus; preclinical immunization; clinical trials; approved vaccine
Show Figures

Figure 1

MDPI and ACS Style

Lundstrom, K. Viral Vectors for COVID-19 Vaccine Development. Viruses 2021, 13, 317.

AMA Style

Lundstrom K. Viral Vectors for COVID-19 Vaccine Development. Viruses. 2021; 13(2):317.

Chicago/Turabian Style

Lundstrom, Kenneth. 2021. "Viral Vectors for COVID-19 Vaccine Development" Viruses 13, no. 2: 317.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop